Loading…
Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy
Background/aim Prostate-specific-membrane-antigen/positron emission tomography (PSMA-PET) detects with high accuracy disease-recurrence, leading to changes in the management of biochemically-recurrent (BCR) prostate cancer (PCa). However, data regarding the oncological outcomes of patients who perfo...
Saved in:
| Published in: | European journal of nuclear medicine and molecular imaging 2022-07, Vol.49 (9), p.3257-3268 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3199-32ba379ae8e9d50b92572ee2e16894dd9dba262652c2697c2df02cd8dc17432e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3199-32ba379ae8e9d50b92572ee2e16894dd9dba262652c2697c2df02cd8dc17432e3 |
| container_end_page | 3268 |
| container_issue | 9 |
| container_start_page | 3257 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 49 |
| creator | Ceci, Francesco Rovera, Guido Iorio, Giuseppe Carlo Guarneri, Alessia Chiofalo, Valeria Passera, Roberto Oderda, Marco Dall’Armellina, Sara Liberini, Virginia Grimaldi, Serena Bellò, Marilena Gontero, Paolo Ricardi, Umberto Deandreis, Désirée |
| description | Background/aim
Prostate-specific-membrane-antigen/positron emission tomography (PSMA-PET) detects with high accuracy disease-recurrence, leading to changes in the management of biochemically-recurrent (BCR) prostate cancer (PCa). However, data regarding the oncological outcomes of patients who performed PSMA-PET are needed. The aim of this study was to evaluate the incidence of clinically relevant events during follow-up in patients who performed PSMA-PET for BCR after radical treatment.
Materials and methods
This analysis included consecutive, hormone-sensitive, hormone-free, recurrent PCa patients (HSPC) enrolled through a prospective study. All patients were eligible for salvage therapy, having at least 24 months of follow-up after PSMA-PET. The primary endpoint was the Event-Free Survival (EFS), defined as the time between the PSMA-PET and the date of event/last follow-up. The Kaplan–Meier method was used to estimate the EFS curves. EFS was also investigated by Cox proportional hazards regression. Events were defined as death, radiological progression, or PSA recurrence after therapy.
Results
One-hundred and seventy-six (
n
= 176) patients were analyzed (median PSA 0.62 [IQR: 0.43–1.00] ng/mL; median follow-up of 35.4 [IQR: 26.5–40.3] months). The EFS was 78.8% at 1 year, 65.2% (2 years), and 52.2% (3 years). Patients experiencing events during study follow-up had a significantly higher median PSA (0.81 [IQR: 0.53–1.28] vs 0.51 [IQR: 0.36–0.80] ng/mL) and a lower PSA doubling time (PSAdt) (5.4 [IQR: 3.7–11.6] vs 12.7 [IQR: 6.6–24.3] months) (
p
0.5 ng/mL, PSAdt ≤ 6 months, and a positive PSMA-PET result were associated with a higher event rate (
p
0.5 ng/mL and PSAdt ≤ 6 months were statistically significant event-predictors in multivariate model (
p
|
| doi_str_mv | 10.1007/s00259-022-05741-9 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9250462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2633902694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3199-32ba379ae8e9d50b92572ee2e16894dd9dba262652c2697c2df02cd8dc17432e3</originalsourceid><addsrcrecordid>eNp9kctu1DAUhiMEohd4ARbIEpt2YWofJ7G9QapGQ4tUxEgd1pbjnMy4yiTBTiL1GXgJnoUnw2XKcFmwsqXz_f-5_Fn2irO3nDF5ERmDQlMGQFkhc071k-yYl1xTyZR-evhLdpSdxHjHGFeg9PPsSBTApVLiOPu6nLEbaRMQSZzC7GfbEtuMGEipvn-7snR1-_GSck5Wy_XFYk18RwK6KYQkI9s-7PoOacQu-tHPSIbQx9GOSJztXDI5u75dLc7JYEefBJFg6ze-apE0fSDRtrPdIBm3GOxw_yJ71tg24svH9zT7_H65XlzTm09XHxaXN9QJrjUVUFkhtUWFui5YpaGQgAjIS6XzutZ1ZaGEsgAHpZYO6oaBq1XtuMwFoDjN3u19h6naYe3SYMG2Zgh-Z8O96a03f1c6vzWbfjapE8tLSAZnjwah_zJhHM3OR4dtazvsp2igFEKz1DxP6Jt_0Lt-Cl1aL1FKFEww8WAIe8ql88WAzWEYzsxD1maftUlZm59ZG51Er_9c4yD5FW4CxB6IqdRtMPzu_R_bH3sgtcY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2683503032</pqid></control><display><type>article</type><title>Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>Ceci, Francesco ; Rovera, Guido ; Iorio, Giuseppe Carlo ; Guarneri, Alessia ; Chiofalo, Valeria ; Passera, Roberto ; Oderda, Marco ; Dall’Armellina, Sara ; Liberini, Virginia ; Grimaldi, Serena ; Bellò, Marilena ; Gontero, Paolo ; Ricardi, Umberto ; Deandreis, Désirée</creator><creatorcontrib>Ceci, Francesco ; Rovera, Guido ; Iorio, Giuseppe Carlo ; Guarneri, Alessia ; Chiofalo, Valeria ; Passera, Roberto ; Oderda, Marco ; Dall’Armellina, Sara ; Liberini, Virginia ; Grimaldi, Serena ; Bellò, Marilena ; Gontero, Paolo ; Ricardi, Umberto ; Deandreis, Désirée</creatorcontrib><description>Background/aim
Prostate-specific-membrane-antigen/positron emission tomography (PSMA-PET) detects with high accuracy disease-recurrence, leading to changes in the management of biochemically-recurrent (BCR) prostate cancer (PCa). However, data regarding the oncological outcomes of patients who performed PSMA-PET are needed. The aim of this study was to evaluate the incidence of clinically relevant events during follow-up in patients who performed PSMA-PET for BCR after radical treatment.
Materials and methods
This analysis included consecutive, hormone-sensitive, hormone-free, recurrent PCa patients (HSPC) enrolled through a prospective study. All patients were eligible for salvage therapy, having at least 24 months of follow-up after PSMA-PET. The primary endpoint was the Event-Free Survival (EFS), defined as the time between the PSMA-PET and the date of event/last follow-up. The Kaplan–Meier method was used to estimate the EFS curves. EFS was also investigated by Cox proportional hazards regression. Events were defined as death, radiological progression, or PSA recurrence after therapy.
Results
One-hundred and seventy-six (
n
= 176) patients were analyzed (median PSA 0.62 [IQR: 0.43–1.00] ng/mL; median follow-up of 35.4 [IQR: 26.5–40.3] months). The EFS was 78.8% at 1 year, 65.2% (2 years), and 52.2% (3 years). Patients experiencing events during study follow-up had a significantly higher median PSA (0.81 [IQR: 0.53–1.28] vs 0.51 [IQR: 0.36–0.80] ng/mL) and a lower PSA doubling time (PSAdt) (5.4 [IQR: 3.7–11.6] vs 12.7 [IQR: 6.6–24.3] months) (
p
< 0.001) compared to event-free patients. The Kaplan–Meier curves showed that PSA > 0.5 ng/mL, PSAdt ≤ 6 months, and a positive PSMA-PET result were associated with a higher event rate (
p
< 0.01). No significant differences of event rates were observed in patients who received changes in therapy management after PSMA-PET vs. patients who did not receive therapy changes. Finally, PSA > 0.5 ng/mL and PSAdt ≤ 6 months were statistically significant event-predictors in multivariate model (
p
< 0.001).
Conclusion
Low PSA and long PSAdt were significant predictors of longer EFS. A lower incidence of events was observed in patients having negative PSMA-PET, since longer EFS was significantly more probable in case of a negative scan.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-022-05741-9</identifier><identifier>PMID: 35217883</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antigens ; Cardiology ; Imaging ; Medicine ; Medicine & Public Health ; Nuclear Medicine ; Oncology ; Oncology – Genitourinary ; Original ; Original Article ; Orthopedics ; Patients ; Positron emission ; Positron emission tomography ; Prostate cancer ; Radiology ; Statistical analysis ; Survival ; Therapy ; Tomography</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2022-07, Vol.49 (9), p.3257-3268</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3199-32ba379ae8e9d50b92572ee2e16894dd9dba262652c2697c2df02cd8dc17432e3</citedby><cites>FETCH-LOGICAL-c3199-32ba379ae8e9d50b92572ee2e16894dd9dba262652c2697c2df02cd8dc17432e3</cites><orcidid>0000-0001-9785-5248</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35217883$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ceci, Francesco</creatorcontrib><creatorcontrib>Rovera, Guido</creatorcontrib><creatorcontrib>Iorio, Giuseppe Carlo</creatorcontrib><creatorcontrib>Guarneri, Alessia</creatorcontrib><creatorcontrib>Chiofalo, Valeria</creatorcontrib><creatorcontrib>Passera, Roberto</creatorcontrib><creatorcontrib>Oderda, Marco</creatorcontrib><creatorcontrib>Dall’Armellina, Sara</creatorcontrib><creatorcontrib>Liberini, Virginia</creatorcontrib><creatorcontrib>Grimaldi, Serena</creatorcontrib><creatorcontrib>Bellò, Marilena</creatorcontrib><creatorcontrib>Gontero, Paolo</creatorcontrib><creatorcontrib>Ricardi, Umberto</creatorcontrib><creatorcontrib>Deandreis, Désirée</creatorcontrib><title>Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Background/aim
Prostate-specific-membrane-antigen/positron emission tomography (PSMA-PET) detects with high accuracy disease-recurrence, leading to changes in the management of biochemically-recurrent (BCR) prostate cancer (PCa). However, data regarding the oncological outcomes of patients who performed PSMA-PET are needed. The aim of this study was to evaluate the incidence of clinically relevant events during follow-up in patients who performed PSMA-PET for BCR after radical treatment.
Materials and methods
This analysis included consecutive, hormone-sensitive, hormone-free, recurrent PCa patients (HSPC) enrolled through a prospective study. All patients were eligible for salvage therapy, having at least 24 months of follow-up after PSMA-PET. The primary endpoint was the Event-Free Survival (EFS), defined as the time between the PSMA-PET and the date of event/last follow-up. The Kaplan–Meier method was used to estimate the EFS curves. EFS was also investigated by Cox proportional hazards regression. Events were defined as death, radiological progression, or PSA recurrence after therapy.
Results
One-hundred and seventy-six (
n
= 176) patients were analyzed (median PSA 0.62 [IQR: 0.43–1.00] ng/mL; median follow-up of 35.4 [IQR: 26.5–40.3] months). The EFS was 78.8% at 1 year, 65.2% (2 years), and 52.2% (3 years). Patients experiencing events during study follow-up had a significantly higher median PSA (0.81 [IQR: 0.53–1.28] vs 0.51 [IQR: 0.36–0.80] ng/mL) and a lower PSA doubling time (PSAdt) (5.4 [IQR: 3.7–11.6] vs 12.7 [IQR: 6.6–24.3] months) (
p
< 0.001) compared to event-free patients. The Kaplan–Meier curves showed that PSA > 0.5 ng/mL, PSAdt ≤ 6 months, and a positive PSMA-PET result were associated with a higher event rate (
p
< 0.01). No significant differences of event rates were observed in patients who received changes in therapy management after PSMA-PET vs. patients who did not receive therapy changes. Finally, PSA > 0.5 ng/mL and PSAdt ≤ 6 months were statistically significant event-predictors in multivariate model (
p
< 0.001).
Conclusion
Low PSA and long PSAdt were significant predictors of longer EFS. A lower incidence of events was observed in patients having negative PSMA-PET, since longer EFS was significantly more probable in case of a negative scan.</description><subject>Antigens</subject><subject>Cardiology</subject><subject>Imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Oncology – Genitourinary</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Prostate cancer</subject><subject>Radiology</subject><subject>Statistical analysis</subject><subject>Survival</subject><subject>Therapy</subject><subject>Tomography</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1DAUhiMEohd4ARbIEpt2YWofJ7G9QapGQ4tUxEgd1pbjnMy4yiTBTiL1GXgJnoUnw2XKcFmwsqXz_f-5_Fn2irO3nDF5ERmDQlMGQFkhc071k-yYl1xTyZR-evhLdpSdxHjHGFeg9PPsSBTApVLiOPu6nLEbaRMQSZzC7GfbEtuMGEipvn-7snR1-_GSck5Wy_XFYk18RwK6KYQkI9s-7PoOacQu-tHPSIbQx9GOSJztXDI5u75dLc7JYEefBJFg6ze-apE0fSDRtrPdIBm3GOxw_yJ71tg24svH9zT7_H65XlzTm09XHxaXN9QJrjUVUFkhtUWFui5YpaGQgAjIS6XzutZ1ZaGEsgAHpZYO6oaBq1XtuMwFoDjN3u19h6naYe3SYMG2Zgh-Z8O96a03f1c6vzWbfjapE8tLSAZnjwah_zJhHM3OR4dtazvsp2igFEKz1DxP6Jt_0Lt-Cl1aL1FKFEww8WAIe8ql88WAzWEYzsxD1maftUlZm59ZG51Er_9c4yD5FW4CxB6IqdRtMPzu_R_bH3sgtcY</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Ceci, Francesco</creator><creator>Rovera, Guido</creator><creator>Iorio, Giuseppe Carlo</creator><creator>Guarneri, Alessia</creator><creator>Chiofalo, Valeria</creator><creator>Passera, Roberto</creator><creator>Oderda, Marco</creator><creator>Dall’Armellina, Sara</creator><creator>Liberini, Virginia</creator><creator>Grimaldi, Serena</creator><creator>Bellò, Marilena</creator><creator>Gontero, Paolo</creator><creator>Ricardi, Umberto</creator><creator>Deandreis, Désirée</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9785-5248</orcidid></search><sort><creationdate>20220701</creationdate><title>Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy</title><author>Ceci, Francesco ; Rovera, Guido ; Iorio, Giuseppe Carlo ; Guarneri, Alessia ; Chiofalo, Valeria ; Passera, Roberto ; Oderda, Marco ; Dall’Armellina, Sara ; Liberini, Virginia ; Grimaldi, Serena ; Bellò, Marilena ; Gontero, Paolo ; Ricardi, Umberto ; Deandreis, Désirée</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3199-32ba379ae8e9d50b92572ee2e16894dd9dba262652c2697c2df02cd8dc17432e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Cardiology</topic><topic>Imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Oncology – Genitourinary</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Prostate cancer</topic><topic>Radiology</topic><topic>Statistical analysis</topic><topic>Survival</topic><topic>Therapy</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ceci, Francesco</creatorcontrib><creatorcontrib>Rovera, Guido</creatorcontrib><creatorcontrib>Iorio, Giuseppe Carlo</creatorcontrib><creatorcontrib>Guarneri, Alessia</creatorcontrib><creatorcontrib>Chiofalo, Valeria</creatorcontrib><creatorcontrib>Passera, Roberto</creatorcontrib><creatorcontrib>Oderda, Marco</creatorcontrib><creatorcontrib>Dall’Armellina, Sara</creatorcontrib><creatorcontrib>Liberini, Virginia</creatorcontrib><creatorcontrib>Grimaldi, Serena</creatorcontrib><creatorcontrib>Bellò, Marilena</creatorcontrib><creatorcontrib>Gontero, Paolo</creatorcontrib><creatorcontrib>Ricardi, Umberto</creatorcontrib><creatorcontrib>Deandreis, Désirée</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ceci, Francesco</au><au>Rovera, Guido</au><au>Iorio, Giuseppe Carlo</au><au>Guarneri, Alessia</au><au>Chiofalo, Valeria</au><au>Passera, Roberto</au><au>Oderda, Marco</au><au>Dall’Armellina, Sara</au><au>Liberini, Virginia</au><au>Grimaldi, Serena</au><au>Bellò, Marilena</au><au>Gontero, Paolo</au><au>Ricardi, Umberto</au><au>Deandreis, Désirée</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>49</volume><issue>9</issue><spage>3257</spage><epage>3268</epage><pages>3257-3268</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Background/aim
Prostate-specific-membrane-antigen/positron emission tomography (PSMA-PET) detects with high accuracy disease-recurrence, leading to changes in the management of biochemically-recurrent (BCR) prostate cancer (PCa). However, data regarding the oncological outcomes of patients who performed PSMA-PET are needed. The aim of this study was to evaluate the incidence of clinically relevant events during follow-up in patients who performed PSMA-PET for BCR after radical treatment.
Materials and methods
This analysis included consecutive, hormone-sensitive, hormone-free, recurrent PCa patients (HSPC) enrolled through a prospective study. All patients were eligible for salvage therapy, having at least 24 months of follow-up after PSMA-PET. The primary endpoint was the Event-Free Survival (EFS), defined as the time between the PSMA-PET and the date of event/last follow-up. The Kaplan–Meier method was used to estimate the EFS curves. EFS was also investigated by Cox proportional hazards regression. Events were defined as death, radiological progression, or PSA recurrence after therapy.
Results
One-hundred and seventy-six (
n
= 176) patients were analyzed (median PSA 0.62 [IQR: 0.43–1.00] ng/mL; median follow-up of 35.4 [IQR: 26.5–40.3] months). The EFS was 78.8% at 1 year, 65.2% (2 years), and 52.2% (3 years). Patients experiencing events during study follow-up had a significantly higher median PSA (0.81 [IQR: 0.53–1.28] vs 0.51 [IQR: 0.36–0.80] ng/mL) and a lower PSA doubling time (PSAdt) (5.4 [IQR: 3.7–11.6] vs 12.7 [IQR: 6.6–24.3] months) (
p
< 0.001) compared to event-free patients. The Kaplan–Meier curves showed that PSA > 0.5 ng/mL, PSAdt ≤ 6 months, and a positive PSMA-PET result were associated with a higher event rate (
p
< 0.01). No significant differences of event rates were observed in patients who received changes in therapy management after PSMA-PET vs. patients who did not receive therapy changes. Finally, PSA > 0.5 ng/mL and PSAdt ≤ 6 months were statistically significant event-predictors in multivariate model (
p
< 0.001).
Conclusion
Low PSA and long PSAdt were significant predictors of longer EFS. A lower incidence of events was observed in patients having negative PSMA-PET, since longer EFS was significantly more probable in case of a negative scan.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35217883</pmid><doi>10.1007/s00259-022-05741-9</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-9785-5248</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2022-07, Vol.49 (9), p.3257-3268 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9250462 |
| source | Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List |
| subjects | Antigens Cardiology Imaging Medicine Medicine & Public Health Nuclear Medicine Oncology Oncology – Genitourinary Original Original Article Orthopedics Patients Positron emission Positron emission tomography Prostate cancer Radiology Statistical analysis Survival Therapy Tomography |
| title | Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A29%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Event-free%20survival%20after%2068%C2%A0Ga-PSMA-11%20PET/CT%20in%20recurrent%20hormone-sensitive%20prostate%20cancer%20(HSPC)%20patients%20eligible%20for%20salvage%20therapy&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Ceci,%20Francesco&rft.date=2022-07-01&rft.volume=49&rft.issue=9&rft.spage=3257&rft.epage=3268&rft.pages=3257-3268&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-022-05741-9&rft_dat=%3Cproquest_pubme%3E2633902694%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3199-32ba379ae8e9d50b92572ee2e16894dd9dba262652c2697c2df02cd8dc17432e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2683503032&rft_id=info:pmid/35217883&rfr_iscdi=true |